• Explore /
  • Poster
  • / Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment (PACE).

Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment (PACE).

Abstract Poster

Authors

null

Jan Alexander Stratmann

University Hospital Frankfurt, Frankfurt, Germany

Jan Alexander Stratmann , Fabian Acker , Lukas Aspacher , Juergen Alt , Friederike C Althoff , Sophie Heinzen , Nicola Gökbuget , Ina Müller , Lena Reiser , Sina Hehn , Hubert Serve , Martin Mänz , Frauke Meyer , Martin Sebastian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

2019-004757-88

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS9157)

DOI

10.1200/JCO.2022.40.16_suppl.TPS9157

Abstract #

TPS9157

Poster Bd #

133a

Abstract Disclosures

Similar Posters

First Author: Jonathan W. Riess

First Author: Alexandra Pender

First Author: Nobuaki Mamesaya

First Author: Daniel Shao-Weng Tan